

Special Issue

Boron in Medicinal Chemistry: From Synthesis to Therapeutic Applications

Message from the Guest Editors

Dear colleagues, In recent years, the interest in boron-based compounds for medical applications has grown significantly, bearing the development of new drugs, e.g., Velcade® (bortezomib), which is used in the treatment of multiple myeloma. This Special Issue is dedicated to all aspects of boron-based compounds with potential pharmaceutical interest, including clusters of boron (carboranes, metallaboranes, metallocarboranes, aminoboranes, etc.), organic and bio-organic boron conjugates (boronic acids and their complexes as well as derivatives, benzoxaboroles), and boron in materials (including polymers and dendrimers), that can have an impact on the medical field, with anticancer, bactericidal, antifungal, and anti-HIV activity, anti-rheumatoid arthritis activity, applications of boron in drug delivery and imaging for diagnosis, or compounds focused on boron neutron capture therapy. It is a pleasure to invite you to submit a manuscript to this Special Issue; regular articles, communications, and reviews are all welcome.

Guest Editors

Dr. Daniela Imperio

Department of Pharmaceutical Sciences, University of Piemonte Orientale, 28100 Novara, Italy

Prof. Dr. Luigi Panza

Department of Pharmaceutical Sciences, University of Piemonte Orientale, 28100 Novara, Italy

Deadline for manuscript submissions

closed (25 February 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/170785

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)